FULL TEST BANK FOR
LEHNE’S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSES AND
PHYSICIAN ASSISTANTS 2ND EDITION BY
JACQUELINE BURCHUM; LAURA D. ROSENTHAL | 2020/2021 |
,TABLE OF CONTENTS
CHAPTER 1: PRESCRIPTIVE AUTHORITY TEST BANK .................................................................................. 5
CHAPTER 2: RATIONAL DRUG SELECTION AND PRESCRIPTION WRITING ................................................. 8
CHAPTER 3: PROMOTING POSITIVE OUTCOMES OF DRUG THERAPY ..................................................... 12
CHAPTER 4: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS ........................ 16
CHAPTER 5: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS .................................................... 23
CHAPTER 6: INDIVIDUAL VARIATION IN DRUG RESPONSES .................................................................... 31
CHAPTER 7 GENETIC AND GENOMIC CONSIDERATIONS IN PHARMACOTHERAPEUTICS ........................ 37
CHAPTER 8: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING ............................................ 45
CHAPTER 9: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................. 50
CHAPTER 10: DRUG THERAPY IN GERIATRIC ........................................................................................... 57
. CHAPTER 11: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .............................................................. 64
. CHAPTER 12: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM..................................................... 68
. CHAPTER 13: MUSCARINIC AGONISTS............................................................................................... 73
CHAPTER 14 MUSCARINIC ANTAGONISTS ............................................................................................... 79
CHAPTER 15: ADRENERGIC AGONISTS .................................................................................................... 83
CHAPTER 16: ADRENERGIC ANTAGONISTS.............................................................................................. 90
CHAPTER 17: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................. 99
CHAPTER 18: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY ............................... 105
CHAPTER 19: DRUGS FOR PARKINSON'S DISEASE ................................................................................. 110
. CHAPTER 20: DRUGS FOR ALZHEIMER'S DISEASE................................................................................ 116
CHAPTER 21: DRUGS FOR SEIZURE DISORDERS .................................................................................... 121
CHAPTER 22: DRUGS FOR MUSCLE SPASM AND SPASTICITY ................................................................ 127
CHAPTER 23: LOCAL ANESTHETICS ........................................................................................................ 132
CHAPTER 24: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS
.............................................................................................................................................................. 139
CHAPTER 25: DRUGS FOR HEADACHE ................................................................................................... 147
. CHAPTER 26: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ...................................... 154
CHAPTER 27: ANTIDEPRESSANTS .......................................................................................................... 163
CHAPTER 28: DRUGS FOR BIPOLAR DISORDER...................................................................................... 169
CHAPTER 29: SEDATIVE-HYPNOTIC DRUGS ........................................................................................... 176
CHAPTER 30: MANAGEMENT OF ANXIETY DISORDERS ......................................................................... 181
CHAPTER 31: CENTRAL NERVOUS SYSTEM STIMULANTS AND ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
.............................................................................................................................................................. 187
,CHAPTER 32: DRUG ABUSE I: BASIC CONSIDERATIONS ......................................................................... 194
CHAPTER 33: DRUG ABUSE II: ALCOHOL ............................................................................................... 198
CHAPTER 34: DRUG ABUSE III: NICOTINE AND SMOKING ..................................................................... 205
. CHAPTER 35: DRUG ABUSE IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE ... 211
CHAPTER 36: REVIEW OF HEMODYNAMICS .......................................................................................... 222
CHAPTER 37: DIURETICS ........................................................................................................................ 226
. CHAPTER 38: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ....................... 231
. CHAPTER 39: CALCIUM CHANNEL BLOCKERS ...................................................................................... 238
CHAPTER 40: VASODILATORS ................................................................................................................ 242
CHAPTER 41: DRUGS FOR HYPERTENSION ............................................................................................ 248
CHAPTER 42: DRUGS FOR HEART FAILURE ............................................................................................ 258
CHAPTER 43: ANTIDYSRHYTHMIC DRUGS ............................................................................................. 270
CHAPTER 44: PROPHYLAXIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: DRUGS THAT HELP
NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................................................................... 281
CHAPTER 45: DRUGS FOR ANGINA PECTORIS ....................................................................................... 291
CHAPTER 46: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ................................... 301
CHAPTER 47: DRUGS FOR DEFICIENCY ANEMIAS .................................................................................. 310
CHAPTER 48: DRUGS FOR DIABETES MELLITUS ..................................................................................... 319
CHAPTER 49: DRUGS FOR THYROID DISORDERS ................................................................................... 327
CHAPTER 50: ESTROGENS AND PROGESTINS: BASIC PHARMACOLOGY AND NONCONTRACEPTIVE APPLICATIONS
.............................................................................................................................................................. 335
CHAPTER 51: BIRTH CONTROL............................................................................................................... 340
CHAPTER 52: ANDROGENS .................................................................................................................... 348
CHAPTER 53: DRUGS FOR ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA ............... 354
CHAPTER 54: REVIEW OF THE IMMUNE SYSTEM .................................................................................. 358
CHAPTER 55: CHILDHOOD IMMUNIZATION .......................................................................................... 363
CHAPTER 56: ANTIHISTAMINES ............................................................................................................. 371
CHAPTER 57: CYCLOOXYGENASE INHIBITORS: NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND
ACETAMINOPHEN
.............................................................................................................................................................. 378
CHAPTER 58: GLUCOCORTICOIDS IN NONENDOCRINE DISORDERS ...................................................... 386
CHAPTER 59: DRUG THERAPY OF RHEUMATOID ARTHRITIS ................................................................. 394
CHAPTER 60: DRUG THERAPY OF GOUT ................................................................................................ 399
CHAPTER 61: DRUGS AFFECTING CALCIUM LEVELS AND BONE MINERALIZATION ............................... 404
,CHAPTER 62: DRUGS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE ................... 412
. CHAPTER 63: DRUGS FOR ALLERGIC RHINITIS, COUGH, AND COLDS .................................................. 423
CHAPTER 64: DRUGS FOR PEPTIC ULCER DISEASE ................................................................................ 430
CHAPTER 65: LAXATIVES........................................................................................................................ 437
CHAPTER 66: OTHER GASTROINTESTINAL DRUGS ................................................................................ 445
CHAPTER 67: VITAMINS......................................................................................................................... 455
CHAPTER 68: DRUGS FOR WEIGHT LOSS ............................................................................................... 462
CHAPTER 69: COMPLEMENTARY AND ALTERNATIVE THERAPIES ......................................................... 469
. CHAPTER 70: BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY .......................................................... 474
CHAPTER 71: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL I: PENICILLINS.................................. 480
CHAPTER 72: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL II: OTHER DRUGS ............................ 487
CHAPTER 73: BACTERIOSTATIC INHIBITORS OF PROTEIN SYNTHESIS ................................................... 494
CHAPTER 74: AMINOGLYCOSIDES: BACTERICIDAL INHIBITORS OF PROTEIN SYNTHESIS ...................... 504
CHAPTER 75: SULFONAMIDES AND TRIMETHOPRIM ............................................................................ 514
CHAPTER 76: DRUG THERAPY OF URINARY TRACT INFECTIONS ........................................................... 521
CHAPTER 77: ANTIMYCOBACTERIAL AGENTS ....................................................................................... 528
CHAPTER 78: MISCELLANEOUS ANTIBACTERIAL DRUGS ....................................................................... 538
CHAPTER 79: ANTIFUNGAL AGENTS ...................................................................................................... 542
CHAPTER 80: ANTIVIRAL AGENTS I: DRUGS FOR NON-HIV VIRAL INFECTIONS ..................................... 554
CHAPTER 81: ANTIVIRAL AGENTS II: DRUGS FOR HIV INFECTION AND RELATED OPPORTUNISTIC INFECTIONS
.............................................................................................................................................................. 562
CHAPTER 82: DRUG THERAPY OF SEXUALLY TRANSWERMITTED DISEASES .......................................... 569
CHAPTER 83: ANTHELMINTICS, ANTIPROTOZOAL DRUGS, AND ECTOPARASITICIDES .......................... 574
CHAPTER 84 INTRODUCTION TO IMMUNOMODULATORS ................................................................... 579
CHAPTER 85: SUPPORTIVE CARE OF PATIENTS RECEIVING ANTICANCER DRUGS ................................. 585
CHAPTER 86: DRUGS FOR CANCER PAIN ............................................................................................... 593
CHAPTER 87: DRUGS FOR THE EYE ........................................................................................................ 602
CHAPTER 88: DRUGS FOR THE SKIN ...................................................................................................... 609
CHAPTER 89: DRUGS FOR THE EAR ....................................................................................................... 620
CHAPTER 90: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ....................... 626
CHAPTER 91: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ....................................... 633
CHAPTER 92: ADDITIONAL ACUTE CARE DRUGS ................................................................................... 639
,CHAPTER 1: PRESCRIPTIVE AUTHORITY TEST BANK
MULTIPLE CHOICE
1. AN APRN WORKS IN A UROLOGY CLINIC UNDER THE SUPERVISION OF A PHYSICIAN WHO DOES
NOT RESTRICT THE TYPES OF MEDICATIONS THE APRN IS ALLOWED TO PRESCRIBE. STATE LAW DOES
NOT REQUIRE THE APRN TO PRACTICE UNDER PHYSICIAN SUPERVISION. HOW WOULD THE APRN’S
PRESCRIPTIVE AUTHORITY BE DESCRIBED?
A. FULL AUTHORITY
B. INDEPENDENT
C. WITHOUT LIMITATION
D. LIMITED AUTHORITY
ANSWER: B
THE APRN HAS INDEPENDENT PRESCRIPTIVE AUTHORITY BECAUSE THE REGULATING BODY DOES NOT
REQUIRE THAT THE APRN WORK UNDER PHYSICIAN SUPERVISION. FULL PRESCRIPTIVE AUTHORITY GIVES
THE PROVIDER THE RIGHT TO PRESCRIBE INDEPENDENTLY AND WITHOUT LIMITATION. LIMITED
AUTHORITY PLACES RESTRICTIONS ON THE TYPES OF DRUGS THAT CAN BE PRESCRIBED.DIF: COGNITIVE
LEVEL: COMPREHENSIONREF: P. 1TOP: NURSING PROCESS: I MSC: NCLEX CLIENT NEEDS CATEGORY:
PHYSIOLOGIC INTEGRITY: PHARMACOLOGIC AND PARENTERAL THERAPIES
2. WHICH FACTORS INCREASE THE NEED FOR APRNS TO HAVE FULL PRESCRIPTIVE AUTHORITY?
A. MORE PATIENTS WILL HAVE ACCESS TO HEALTH CARE.
B. ENROLLMENT IN MEDICAL SCHOOLS IS PREDICTED TO DECREASE.
C. PHYSICIAN’S ASSISTANTS ARE BEING UTILIZED LESS OFTEN.
D. APRN EDUCATION IS MORE COMPLEX THAN EDUCATION FOR PHYSICIANS.
ANSWER: A
IMPLEMENTATION OF THE AFFORDABLE CARE ACT HAS INCREASED THE NUMBER OF INDIVIDUALS WITH
HEALTH CARE COVERAGE, AND THUS THE NUMBER WHO HAVE ACCESS TO HEALTH CARE SERVICES. THE
INCREASE IN THE NUMBER OF PATIENTS CREATES THE NEED FOR MORE PROVIDERS WITH PRESCRIPTIVE
AUTHORITY. APRNS CAN FILL THIS
,PRACTICE GAP.DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 2TOP: NURSING PROCESS:
IMPLEMENTATION MSC: NCLEX CLIENT NEEDS CATEGORY: PHYSIOLOGIC INTEGRITY: PHARMACOLOGIC
AND PARENTERAL THERAPIES
3. WHICH FACTORS COULD BE ATTRIBUTED TO LIMITED PRESCRIPTIVE AUTHORITY FOR APRNS?
SELECT ALL THAT APPLY.
A. INACCESSIBILITY OF PATIENT CARE
B. HIGHER HEALTH CARE COSTS
C. HIGHER QUALITY MEDICAL TREATMENT
D. IMPROVED COLLABORATIVE CARE
E. ENHANCED HEALTH LITERACY
ANSWER: A , B
LIMITING PRESCRIPTIVE AUTHORITY FOR APRNS CAN CREATE BARRIERS TO QUALITY, AFFORDABLE, AND
ACCESSIBLE PATIENT CARE. IT MAY ALSO LEAD TO POOR COLLABORATION AMONG PROVIDERS AND
HIGHER HEALTH CARE COSTS. IT WOULD NOT DIRECTLY IMPACT PATIENT’S HEALTH LITERACY. DIF:
COGNITIVE LEVEL: COMPREHENSION REF:
P. 2TOP: NURSING PROCESS: IMPLEMENTATION MSC: NCLEX CLIENT NEEDS CATEGORY: PHYSIOLOGIC
INTEGRITY: PHARMACOLOGIC AND PARENTERAL THERAPIES
4. WHICH ASPECTS SUPPORT THE APRN’S PROVISION FOR FULL PRESCRIPTIVE AUTHORITY?
SELECT ALL THAT APPLY.
A. CLINICAL EDUCATION INCLUDES PRESCRIPTION OF MEDICATIONS AND DISEASE PROCESSES.
B. FEDERAL REGULATIONS SUPPORT THE PROVISION OF FULL AUTHORITY FOR APRNS.
C. NATIONAL EXAMINATIONS PROVIDE VALIDATION OF THE APRN’S ABILITY TO PROVIDE SAFECARE.
D. LICENSURE ENSURES COMPLIANCE WITH HEALTH CARE AND SAFETY STANDARDS.
E. LIMITING PROVISION CAN DECREASE HEALTH CARE AFFORDABILITY.
, ANSWER: A , C , D
APRNS ARE EDUCATED TO PRACTICE AND PRESCRIBE INDEPENDENTLY WITHOUT SUPERVISION.
NATIONAL EXAMINATIONS VALIDATE THE ABILITY TO PROVIDE SAFE AND COMPETENT CARE.
LICENSURE ENSURES COMPLIANCE WITH STANDARDS TO PROMOTE PUBLIC HEALTH AND SAFETY.
LIMITED PRESCRIPTIVE AUTHORITY CREATES NUMEROUS BARRIERS TO QUALITY, AFFORDABLE, AND
ACCESSIBLE PATIENT CARE.DIF: COGNITIVE LEVEL: COMPREHENSIONREF: PP. 1-2TOP: NURSING
PROCESS: IMPLEMENTATION MSC: NCLEX CLIENT NEEDS CATEGORY: PHYSIOLOGIC INTEGRITY:
PHARMACOLOGIC AND PARENTERAL THERAPIES
5. WHICH ASPECTS SUPPORT THE APRN’S PROVISION FOR FULL PRESCRIPTIVE AUTHORITY?
SELECT ALL THAT APPLY.
A. CLINICAL EDUCATION INCLUDES PRESCRIPTION OF MEDICATIONS AND DISEASE PROCESSES.
B. FEDERAL REGULATIONS SUPPORT THE PROVISION OF FULL AUTHORITY FOR APRNS.
C. NATIONAL EXAMINATIONS PROVIDE VALIDATION OF THE APRN’S ABILITY TO PROVIDE SAFECARE.
D. LICENSURE ENSURES COMPLIANCE WITH HEALTH CARE AND SAFETY STANDARDS.
ANSWER: A , C , D
APRNS ARE EDUCATED TO PRACTICE AND PRESCRIBE INDEPENDENTLY WITHOUT SUPERVISION.
NATIONAL EXAMINATIONS VALIDATE THE ABILITY TO PROVIDE SAFE AND COMPETENT CARE. LICENSURE
ENSURES COMPLIANCE WITH STANDARDS TO PROMOTE PUBLIC HEALTH AND SAFETY. LIMITED
PRESCRIPTIVE AUTHORITY CREATES NUMEROUS BARRIERS TO QUALITY, AFFORDABLE, AND ACCESSIBLE
PATIENT CARE.DIF: COGNITIVE LEVEL:
COMPREHENSIONREF: PP. 1-2TOP: NURSING PROCESS: IMPLEMENTATION MSC: NCLEX
CLIENT NEEDS CATEGORY: PHYSIOLOGIC INTEGRITY: PHARMACOLOGIC AND PARENTERAL
THERAPIES
6. A FAMILY NURSE PRACTITIONER PRACTICING IN MAINE IS HIRED AT A PRACTICE ACROSS
STATE LINES IN VIRGINIA. WHICH ASPECT OF PRACTICE MAY CHANGE FOR THE APRN?
A. THE APRN WILL HAVE LESS PRESCRIPTIVE AUTHORITY IN THE NEW POSITION.
B. THE APRN WILL HAVE MORE PRESCRIPTIVE AUTHORITY IN THE NEW POSITION.
LEHNE’S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSES AND
PHYSICIAN ASSISTANTS 2ND EDITION BY
JACQUELINE BURCHUM; LAURA D. ROSENTHAL | 2020/2021 |
,TABLE OF CONTENTS
CHAPTER 1: PRESCRIPTIVE AUTHORITY TEST BANK .................................................................................. 5
CHAPTER 2: RATIONAL DRUG SELECTION AND PRESCRIPTION WRITING ................................................. 8
CHAPTER 3: PROMOTING POSITIVE OUTCOMES OF DRUG THERAPY ..................................................... 12
CHAPTER 4: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS ........................ 16
CHAPTER 5: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS .................................................... 23
CHAPTER 6: INDIVIDUAL VARIATION IN DRUG RESPONSES .................................................................... 31
CHAPTER 7 GENETIC AND GENOMIC CONSIDERATIONS IN PHARMACOTHERAPEUTICS ........................ 37
CHAPTER 8: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING ............................................ 45
CHAPTER 9: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................. 50
CHAPTER 10: DRUG THERAPY IN GERIATRIC ........................................................................................... 57
. CHAPTER 11: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .............................................................. 64
. CHAPTER 12: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM..................................................... 68
. CHAPTER 13: MUSCARINIC AGONISTS............................................................................................... 73
CHAPTER 14 MUSCARINIC ANTAGONISTS ............................................................................................... 79
CHAPTER 15: ADRENERGIC AGONISTS .................................................................................................... 83
CHAPTER 16: ADRENERGIC ANTAGONISTS.............................................................................................. 90
CHAPTER 17: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................. 99
CHAPTER 18: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY ............................... 105
CHAPTER 19: DRUGS FOR PARKINSON'S DISEASE ................................................................................. 110
. CHAPTER 20: DRUGS FOR ALZHEIMER'S DISEASE................................................................................ 116
CHAPTER 21: DRUGS FOR SEIZURE DISORDERS .................................................................................... 121
CHAPTER 22: DRUGS FOR MUSCLE SPASM AND SPASTICITY ................................................................ 127
CHAPTER 23: LOCAL ANESTHETICS ........................................................................................................ 132
CHAPTER 24: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS
.............................................................................................................................................................. 139
CHAPTER 25: DRUGS FOR HEADACHE ................................................................................................... 147
. CHAPTER 26: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ...................................... 154
CHAPTER 27: ANTIDEPRESSANTS .......................................................................................................... 163
CHAPTER 28: DRUGS FOR BIPOLAR DISORDER...................................................................................... 169
CHAPTER 29: SEDATIVE-HYPNOTIC DRUGS ........................................................................................... 176
CHAPTER 30: MANAGEMENT OF ANXIETY DISORDERS ......................................................................... 181
CHAPTER 31: CENTRAL NERVOUS SYSTEM STIMULANTS AND ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
.............................................................................................................................................................. 187
,CHAPTER 32: DRUG ABUSE I: BASIC CONSIDERATIONS ......................................................................... 194
CHAPTER 33: DRUG ABUSE II: ALCOHOL ............................................................................................... 198
CHAPTER 34: DRUG ABUSE III: NICOTINE AND SMOKING ..................................................................... 205
. CHAPTER 35: DRUG ABUSE IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE ... 211
CHAPTER 36: REVIEW OF HEMODYNAMICS .......................................................................................... 222
CHAPTER 37: DIURETICS ........................................................................................................................ 226
. CHAPTER 38: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ....................... 231
. CHAPTER 39: CALCIUM CHANNEL BLOCKERS ...................................................................................... 238
CHAPTER 40: VASODILATORS ................................................................................................................ 242
CHAPTER 41: DRUGS FOR HYPERTENSION ............................................................................................ 248
CHAPTER 42: DRUGS FOR HEART FAILURE ............................................................................................ 258
CHAPTER 43: ANTIDYSRHYTHMIC DRUGS ............................................................................................. 270
CHAPTER 44: PROPHYLAXIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: DRUGS THAT HELP
NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................................................................... 281
CHAPTER 45: DRUGS FOR ANGINA PECTORIS ....................................................................................... 291
CHAPTER 46: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ................................... 301
CHAPTER 47: DRUGS FOR DEFICIENCY ANEMIAS .................................................................................. 310
CHAPTER 48: DRUGS FOR DIABETES MELLITUS ..................................................................................... 319
CHAPTER 49: DRUGS FOR THYROID DISORDERS ................................................................................... 327
CHAPTER 50: ESTROGENS AND PROGESTINS: BASIC PHARMACOLOGY AND NONCONTRACEPTIVE APPLICATIONS
.............................................................................................................................................................. 335
CHAPTER 51: BIRTH CONTROL............................................................................................................... 340
CHAPTER 52: ANDROGENS .................................................................................................................... 348
CHAPTER 53: DRUGS FOR ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA ............... 354
CHAPTER 54: REVIEW OF THE IMMUNE SYSTEM .................................................................................. 358
CHAPTER 55: CHILDHOOD IMMUNIZATION .......................................................................................... 363
CHAPTER 56: ANTIHISTAMINES ............................................................................................................. 371
CHAPTER 57: CYCLOOXYGENASE INHIBITORS: NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND
ACETAMINOPHEN
.............................................................................................................................................................. 378
CHAPTER 58: GLUCOCORTICOIDS IN NONENDOCRINE DISORDERS ...................................................... 386
CHAPTER 59: DRUG THERAPY OF RHEUMATOID ARTHRITIS ................................................................. 394
CHAPTER 60: DRUG THERAPY OF GOUT ................................................................................................ 399
CHAPTER 61: DRUGS AFFECTING CALCIUM LEVELS AND BONE MINERALIZATION ............................... 404
,CHAPTER 62: DRUGS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE ................... 412
. CHAPTER 63: DRUGS FOR ALLERGIC RHINITIS, COUGH, AND COLDS .................................................. 423
CHAPTER 64: DRUGS FOR PEPTIC ULCER DISEASE ................................................................................ 430
CHAPTER 65: LAXATIVES........................................................................................................................ 437
CHAPTER 66: OTHER GASTROINTESTINAL DRUGS ................................................................................ 445
CHAPTER 67: VITAMINS......................................................................................................................... 455
CHAPTER 68: DRUGS FOR WEIGHT LOSS ............................................................................................... 462
CHAPTER 69: COMPLEMENTARY AND ALTERNATIVE THERAPIES ......................................................... 469
. CHAPTER 70: BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY .......................................................... 474
CHAPTER 71: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL I: PENICILLINS.................................. 480
CHAPTER 72: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL II: OTHER DRUGS ............................ 487
CHAPTER 73: BACTERIOSTATIC INHIBITORS OF PROTEIN SYNTHESIS ................................................... 494
CHAPTER 74: AMINOGLYCOSIDES: BACTERICIDAL INHIBITORS OF PROTEIN SYNTHESIS ...................... 504
CHAPTER 75: SULFONAMIDES AND TRIMETHOPRIM ............................................................................ 514
CHAPTER 76: DRUG THERAPY OF URINARY TRACT INFECTIONS ........................................................... 521
CHAPTER 77: ANTIMYCOBACTERIAL AGENTS ....................................................................................... 528
CHAPTER 78: MISCELLANEOUS ANTIBACTERIAL DRUGS ....................................................................... 538
CHAPTER 79: ANTIFUNGAL AGENTS ...................................................................................................... 542
CHAPTER 80: ANTIVIRAL AGENTS I: DRUGS FOR NON-HIV VIRAL INFECTIONS ..................................... 554
CHAPTER 81: ANTIVIRAL AGENTS II: DRUGS FOR HIV INFECTION AND RELATED OPPORTUNISTIC INFECTIONS
.............................................................................................................................................................. 562
CHAPTER 82: DRUG THERAPY OF SEXUALLY TRANSWERMITTED DISEASES .......................................... 569
CHAPTER 83: ANTHELMINTICS, ANTIPROTOZOAL DRUGS, AND ECTOPARASITICIDES .......................... 574
CHAPTER 84 INTRODUCTION TO IMMUNOMODULATORS ................................................................... 579
CHAPTER 85: SUPPORTIVE CARE OF PATIENTS RECEIVING ANTICANCER DRUGS ................................. 585
CHAPTER 86: DRUGS FOR CANCER PAIN ............................................................................................... 593
CHAPTER 87: DRUGS FOR THE EYE ........................................................................................................ 602
CHAPTER 88: DRUGS FOR THE SKIN ...................................................................................................... 609
CHAPTER 89: DRUGS FOR THE EAR ....................................................................................................... 620
CHAPTER 90: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ....................... 626
CHAPTER 91: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ....................................... 633
CHAPTER 92: ADDITIONAL ACUTE CARE DRUGS ................................................................................... 639
,CHAPTER 1: PRESCRIPTIVE AUTHORITY TEST BANK
MULTIPLE CHOICE
1. AN APRN WORKS IN A UROLOGY CLINIC UNDER THE SUPERVISION OF A PHYSICIAN WHO DOES
NOT RESTRICT THE TYPES OF MEDICATIONS THE APRN IS ALLOWED TO PRESCRIBE. STATE LAW DOES
NOT REQUIRE THE APRN TO PRACTICE UNDER PHYSICIAN SUPERVISION. HOW WOULD THE APRN’S
PRESCRIPTIVE AUTHORITY BE DESCRIBED?
A. FULL AUTHORITY
B. INDEPENDENT
C. WITHOUT LIMITATION
D. LIMITED AUTHORITY
ANSWER: B
THE APRN HAS INDEPENDENT PRESCRIPTIVE AUTHORITY BECAUSE THE REGULATING BODY DOES NOT
REQUIRE THAT THE APRN WORK UNDER PHYSICIAN SUPERVISION. FULL PRESCRIPTIVE AUTHORITY GIVES
THE PROVIDER THE RIGHT TO PRESCRIBE INDEPENDENTLY AND WITHOUT LIMITATION. LIMITED
AUTHORITY PLACES RESTRICTIONS ON THE TYPES OF DRUGS THAT CAN BE PRESCRIBED.DIF: COGNITIVE
LEVEL: COMPREHENSIONREF: P. 1TOP: NURSING PROCESS: I MSC: NCLEX CLIENT NEEDS CATEGORY:
PHYSIOLOGIC INTEGRITY: PHARMACOLOGIC AND PARENTERAL THERAPIES
2. WHICH FACTORS INCREASE THE NEED FOR APRNS TO HAVE FULL PRESCRIPTIVE AUTHORITY?
A. MORE PATIENTS WILL HAVE ACCESS TO HEALTH CARE.
B. ENROLLMENT IN MEDICAL SCHOOLS IS PREDICTED TO DECREASE.
C. PHYSICIAN’S ASSISTANTS ARE BEING UTILIZED LESS OFTEN.
D. APRN EDUCATION IS MORE COMPLEX THAN EDUCATION FOR PHYSICIANS.
ANSWER: A
IMPLEMENTATION OF THE AFFORDABLE CARE ACT HAS INCREASED THE NUMBER OF INDIVIDUALS WITH
HEALTH CARE COVERAGE, AND THUS THE NUMBER WHO HAVE ACCESS TO HEALTH CARE SERVICES. THE
INCREASE IN THE NUMBER OF PATIENTS CREATES THE NEED FOR MORE PROVIDERS WITH PRESCRIPTIVE
AUTHORITY. APRNS CAN FILL THIS
,PRACTICE GAP.DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 2TOP: NURSING PROCESS:
IMPLEMENTATION MSC: NCLEX CLIENT NEEDS CATEGORY: PHYSIOLOGIC INTEGRITY: PHARMACOLOGIC
AND PARENTERAL THERAPIES
3. WHICH FACTORS COULD BE ATTRIBUTED TO LIMITED PRESCRIPTIVE AUTHORITY FOR APRNS?
SELECT ALL THAT APPLY.
A. INACCESSIBILITY OF PATIENT CARE
B. HIGHER HEALTH CARE COSTS
C. HIGHER QUALITY MEDICAL TREATMENT
D. IMPROVED COLLABORATIVE CARE
E. ENHANCED HEALTH LITERACY
ANSWER: A , B
LIMITING PRESCRIPTIVE AUTHORITY FOR APRNS CAN CREATE BARRIERS TO QUALITY, AFFORDABLE, AND
ACCESSIBLE PATIENT CARE. IT MAY ALSO LEAD TO POOR COLLABORATION AMONG PROVIDERS AND
HIGHER HEALTH CARE COSTS. IT WOULD NOT DIRECTLY IMPACT PATIENT’S HEALTH LITERACY. DIF:
COGNITIVE LEVEL: COMPREHENSION REF:
P. 2TOP: NURSING PROCESS: IMPLEMENTATION MSC: NCLEX CLIENT NEEDS CATEGORY: PHYSIOLOGIC
INTEGRITY: PHARMACOLOGIC AND PARENTERAL THERAPIES
4. WHICH ASPECTS SUPPORT THE APRN’S PROVISION FOR FULL PRESCRIPTIVE AUTHORITY?
SELECT ALL THAT APPLY.
A. CLINICAL EDUCATION INCLUDES PRESCRIPTION OF MEDICATIONS AND DISEASE PROCESSES.
B. FEDERAL REGULATIONS SUPPORT THE PROVISION OF FULL AUTHORITY FOR APRNS.
C. NATIONAL EXAMINATIONS PROVIDE VALIDATION OF THE APRN’S ABILITY TO PROVIDE SAFECARE.
D. LICENSURE ENSURES COMPLIANCE WITH HEALTH CARE AND SAFETY STANDARDS.
E. LIMITING PROVISION CAN DECREASE HEALTH CARE AFFORDABILITY.
, ANSWER: A , C , D
APRNS ARE EDUCATED TO PRACTICE AND PRESCRIBE INDEPENDENTLY WITHOUT SUPERVISION.
NATIONAL EXAMINATIONS VALIDATE THE ABILITY TO PROVIDE SAFE AND COMPETENT CARE.
LICENSURE ENSURES COMPLIANCE WITH STANDARDS TO PROMOTE PUBLIC HEALTH AND SAFETY.
LIMITED PRESCRIPTIVE AUTHORITY CREATES NUMEROUS BARRIERS TO QUALITY, AFFORDABLE, AND
ACCESSIBLE PATIENT CARE.DIF: COGNITIVE LEVEL: COMPREHENSIONREF: PP. 1-2TOP: NURSING
PROCESS: IMPLEMENTATION MSC: NCLEX CLIENT NEEDS CATEGORY: PHYSIOLOGIC INTEGRITY:
PHARMACOLOGIC AND PARENTERAL THERAPIES
5. WHICH ASPECTS SUPPORT THE APRN’S PROVISION FOR FULL PRESCRIPTIVE AUTHORITY?
SELECT ALL THAT APPLY.
A. CLINICAL EDUCATION INCLUDES PRESCRIPTION OF MEDICATIONS AND DISEASE PROCESSES.
B. FEDERAL REGULATIONS SUPPORT THE PROVISION OF FULL AUTHORITY FOR APRNS.
C. NATIONAL EXAMINATIONS PROVIDE VALIDATION OF THE APRN’S ABILITY TO PROVIDE SAFECARE.
D. LICENSURE ENSURES COMPLIANCE WITH HEALTH CARE AND SAFETY STANDARDS.
ANSWER: A , C , D
APRNS ARE EDUCATED TO PRACTICE AND PRESCRIBE INDEPENDENTLY WITHOUT SUPERVISION.
NATIONAL EXAMINATIONS VALIDATE THE ABILITY TO PROVIDE SAFE AND COMPETENT CARE. LICENSURE
ENSURES COMPLIANCE WITH STANDARDS TO PROMOTE PUBLIC HEALTH AND SAFETY. LIMITED
PRESCRIPTIVE AUTHORITY CREATES NUMEROUS BARRIERS TO QUALITY, AFFORDABLE, AND ACCESSIBLE
PATIENT CARE.DIF: COGNITIVE LEVEL:
COMPREHENSIONREF: PP. 1-2TOP: NURSING PROCESS: IMPLEMENTATION MSC: NCLEX
CLIENT NEEDS CATEGORY: PHYSIOLOGIC INTEGRITY: PHARMACOLOGIC AND PARENTERAL
THERAPIES
6. A FAMILY NURSE PRACTITIONER PRACTICING IN MAINE IS HIRED AT A PRACTICE ACROSS
STATE LINES IN VIRGINIA. WHICH ASPECT OF PRACTICE MAY CHANGE FOR THE APRN?
A. THE APRN WILL HAVE LESS PRESCRIPTIVE AUTHORITY IN THE NEW POSITION.
B. THE APRN WILL HAVE MORE PRESCRIPTIVE AUTHORITY IN THE NEW POSITION.
